Drug Search Results
More Filters [+]

Cefoxitin

Alternative Names: cefoxitin, cefoxitina, mefoxin, mefoxin in plastic container
Latest Update: 2024-12-11
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Cell Wall Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous,Intramuscular,Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Bangladesh | Brazil | Canada | Chile | China | Colombia | Egypt | Estonia | France | Germany | Greece | Ireland | Italy | Jordan | Korea | Lebanon | New Zealand | Pakistan | Peru | Philippines | Portugal | Russia | Saudi Arabia | Slovenia | South Africa | Spain | Taiwan | Thailand | United Kingdom | United States | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: CHU DE POITIERS
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Cefoxitin

Countries in Clinic:

Active Clinical Trial Count: 1

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2022-003262-20

P3

Active, not recruiting

Unknown

2026-01-19

Recent News Events

Date

Type

Title